According to Vitrolife AB's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 43.9584. At the end of 2023 the company had a P/E ratio of -6.85.
Year | P/E ratio | Change |
---|---|---|
2023 | -6.85 | -110.7% |
2022 | 64.0 | -66.06% |
2021 | 189 | 130.67% |
2020 | 81.7 | 46.1% |
2019 | 55.9 | 6.23% |
2018 | 52.7 | 2.71% |
2017 | 51.3 | 16.2% |
2016 | 44.1 | 28.79% |
2015 | 34.3 | 12.7% |
2014 | 30.4 | -8.39% |
2013 | 33.2 | 1292.86% |
2012 | 2.38 | -87.77% |
2011 | 19.5 | 13.42% |
2010 | 17.2 | 28.44% |
2009 | 13.4 | 31.99% |
2008 | 10.1 | -6.74% |
2007 | 10.9 | -63.95% |
2006 | 30.1 | 34.42% |
2005 | 22.4 | 15% |
2004 | 19.5 | 206.24% |
2003 | 6.36 | 449.67% |
2002 | 1.16 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.